Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALVRNASDAQ:EVAXNASDAQ:LIPONASDAQ:ME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$2.40-6.6%$4.31$7.96▼$24.15$12.10M0.6316,718 shs150,164 shsEVAXEvaxion A/S$2.32+6.9%$1.95$1.20▼$17.75$3.25M0.09617,860 shs93,633 shsLIPOLipella Pharmaceuticals$1.65-30.1%$2.62$1.61▼$12.00$10.54M0.44728,007 shs189,783 shsME23andMe$0.50-35.3%$0.50$0.53▼$10.81$13.36M1.191.42 million shs29.28 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir-6.61%-9.09%-19.46%-78.18%-85.94%EVAXEvaxion A/S0.00%-16.25%+24.06%+22.75%-82.62%LIPOLipella Pharmaceuticals0.00%-35.52%-43.88%-36.29%-67.62%ME23andMe0.00%0.00%0.00%-72.18%-93.91%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALVRAlloVirN/AN/AN/AN/AN/AN/AN/AN/AEVAXEvaxion A/S1.6187 of 5 stars3.52.00.00.01.11.70.0LIPOLipella Pharmaceuticals1.4372 of 5 stars0.05.00.00.01.93.30.0ME23andMeN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVRAlloVir 0.00N/AN/AN/AEVAXEvaxion A/S 3.00Buy$10.00331.03% UpsideLIPOLipella Pharmaceuticals 0.00N/AN/AN/AME23andMe 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest EVAX, ME, ALVR, and LIPO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2025EVAXEvaxion A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.003/22/2025ME23andMeWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/AEVAXEvaxion A/S$3.34M0.97N/AN/A($1.18) per share-1.97LIPOLipella Pharmaceuticals$540K13.66N/AN/A$1.59 per share1.04ME23andMe$208.78M0.06$0.54 per share0.93$2.34 per share0.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%8/7/2025 (Estimated)EVAXEvaxion A/S-$10.57M-$1.16N/AN/AN/A-316.03%-532.72%-78.32%8/13/2025 (Estimated)LIPOLipella Pharmaceuticals-$5.02M-$4.08N/A∞N/A-988.83%-224.08%-172.88%N/AME23andMe-$666.70M-$15.45N/A∞N/A-183.39%-170.07%-62.13%N/ALatest EVAX, ME, ALVR, and LIPO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/27/2025Q1 2025EVAXEvaxion A/S-$0.65-$0.29+$0.36-$0.29$0.06 millionN/A5/14/2025Q1 2025LIPOLipella PharmaceuticalsN/A-$0.64N/A-$0.64N/A$0.13 million4/1/2025Q4 2024EVAXEvaxion A/S-$0.26-$0.07+$0.19-$0.07$1.66 million$0.12 million3/27/2025Q4 2024LIPOLipella Pharmaceuticals-$2.43-$1.19+$1.24-$1.19N/A$0.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALVRAlloVirN/AN/AN/AN/AN/AEVAXEvaxion A/SN/AN/AN/AN/AN/ALIPOLipella PharmaceuticalsN/AN/AN/AN/AN/AME23andMeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVRAlloVirN/A86.7886.78EVAXEvaxion A/SN/A2.012.01LIPOLipella PharmaceuticalsN/A6.216.21ME23andMeN/A1.050.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVRAlloVir66.05%EVAXEvaxion A/S11.04%LIPOLipella Pharmaceuticals74.31%ME23andMe36.10%Insider OwnershipCompanyInsider OwnershipALVRAlloVir32.07%EVAXEvaxion A/S41.64%LIPOLipella Pharmaceuticals32.11%ME23andMe26.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVRAlloVir1105.04 million3.43 millionOptionableEVAXEvaxion A/S601.40 million819,000No DataLIPOLipella Pharmaceuticals44.47 million3.03 millionNot OptionableME23andMe77026.83 million19.77 millionNot OptionableEVAX, ME, ALVR, and LIPO HeadlinesRecent News About These CompaniesCan 23andMe sell customers' DNA data? Bankruptcy hearing continued FridayJune 20 at 9:48 PM | stltoday.com23andMe Bankruptcy Judge to Rule Soon on Genetic Data Asset SaleJune 20 at 9:48 PM | news.bloomberglaw.comThe Score: 23andMe, U.S. Steel, Accenture and More Stocks That Defined the WeekJune 20 at 4:47 PM | wsj.com23andMe’s ex-CEO is trying to buy the company. A St. Louis judge could decide Friday.June 20 at 11:46 AM | stltoday.comICO Imposes 2.31 Million Pound Fine on 23andMeJune 19 at 1:10 PM | govinfosecurity.com23andMe Could Owe You Up to $10,000 After Its Data Breach SettlementJune 19 at 1:10 PM | cnet.com23andMe Bankruptcy Judge Rejects Texas Effort to Halt Data SaleJune 18, 2025 | news.bloomberglaw.comBattle for 23andMe (and its data) growsJune 18, 2025 | finance.yahoo.comGene data: British data protection fine for 23andmeJune 18, 2025 | heise.deOklahoma files federal lawsuit against 23andMeJune 17, 2025 | kgou.org23andMe fined millions by watchdog after ‘profoundly damaging’ cyber attack exposing genetic dataJune 17, 2025 | lbc.co.ukUK Watchdogs Fine 23andMe $3.1M for Data Security ViolationsJune 17, 2025 | msn.comAnne Wojcicki on genetic privacy, data security and the money behind her bid for 23andMeJune 17, 2025 | bizjournals.com23andMe co-founder wins bid to take back control of companyJune 17, 2025 | massdevice.comICO fines bankrupt 23andMe £2.3m for massive privacy breachJune 17, 2025 | sharecast.comAnne Wojcicki wins bid to buy back 23andMe for $305MJune 17, 2025 | medtechdive.comUK regulator fines 23andMe over massive genetic data breachJune 17, 2025 | biometricupdate.com23andMe co-founder Anne Wojcicki regains control of bankrupt genetic testing companyJune 17, 2025 | msn.com23andMe's Co-Founder to Buy Company; Makes Privacy PledgeJune 17, 2025 | govinfosecurity.com23andMe fined £2.31m over UK users' genetic data breachJune 17, 2025 | pharmaphorum.comOne Tech Tip: How to protect your 23andMe genetic dataJune 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsCoca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyBy Chris Markoch | May 29, 2025View Coca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyEVAX, ME, ALVR, and LIPO Company DescriptionsAlloVir NASDAQ:ALVR$2.40 -0.17 (-6.61%) As of 06/20/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Evaxion A/S NASDAQ:EVAX$2.32 +0.15 (+6.91%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.26 -0.05 (-2.37%) As of 06/20/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.Lipella Pharmaceuticals NASDAQ:LIPO$1.65 -0.71 (-30.08%) As of 06/20/2025 03:59 PM EasternLipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.23andMe NASDAQ:ME$0.50 -0.27 (-35.32%) Closing price 03/28/2025Extended Trading$0.50 0.00 (0.00%) As of 03/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
